Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

Latigo Biotherapeutics has secured $150m in a Series B financing round, which will be used to further the development of its ...

Congress and the Florida Legislature must eliminate cost disparities between opioid and non-opioid options.

Ark is already conducting studies with this new class of pain medication, leveraging its strong infrastructure, experienced staff, and extensive access to patient populations. With strong community ...

Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments ...

To read more letters to the editor, go to oregonlive.com/opinion.

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...

"We need to pass legislation that ensures patients have better access to FDA-approved, non-opioid pain management ...

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective ...

The FDA’s landmark approval of Journavx (suzetrigine)—the first non-opioid pain reliever in over two decades—represents a breakthrough in pain management. This breakthrough underscores the ...

Other contributors included Sanofi Ventures, Deep Track Capital, Qatar Investment Authority and Cormorant Asset Management ... “The need for non-opioid pain treatments has never been more ...